Navigation Links
Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Aires Pharmaceuticals, Inc., announced today that it has successfully completed a $20 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P.  Additionally, Aires further bolstered its cash reserves by entering into an agreement with Novartis International Pharmaceutical Limited whereby Novartis has been granted an exclusive option to acquire Aires following the successful completion of a Phase 2 clinical study of Aironite™ to treat pulmonary arterial hypertension.  The agreement also includes a right to an exclusive worldwide license under pre-agreed conditions.  Including the initial acquisition payment plus potential additional regulatory and sales milestone payments, the deal with Novartis could reach $250 million.

The Series B financing includes new investor MPM Capital and the existing investor, ProQuest Investments.  Dr. William Greene, Managing Director of MPM Capital, will join Aires' Board of Directors.

"ProQuest Investments created Aires and has been a dedicated backer of the company since inception.  We are pleased that MPM and ProQuest will support the company, and along with Novartis share our enthusiasm for the potential of Aironite to help patients with pulmonary arterial hypertension," said Wendy Johnson, Founder, President and CEO of Aires.  The current financing will be sufficient to complete the planned clinical development program.

William Greene, M.D., Managing Director at MPM Capital, said, "We at MPM are excited about the potential of Aironite to impact the lives of pulmonary arterial hypertension patients and look forward to working with Aires in developing this novel approach to a devastating disease."

About Aironite™  

Aironite™ is an inhaled nitric oxide prodrug that has been shown in animal models to cause vasodilatation as well as potentially prevent or reverse the pulmonary artery smooth muscle cell proliferation associated with pulmonary arterial hypertension.  Significant preclinical development has been conducted by inventors Dr. Mark Gladwin and colleagues, formerly from the National Heart, Lung and Blood Institute of the NIH.  In early clinical trials conducted by Aires, Aironite administration resulted in nitric oxide production and reduction of pulmonary artery pressure.

About MPM Capital  

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.

About ProQuest Investments

Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management.  With a proven superior track record and over 40 investments the portfolio reflects the rich diversity of the healthcare industry and exemplifies commitment to fostering the growth of exceptional businesses.

About Aires Pharmaceuticals

Aires Pharmaceuticals, Inc., is a privately held drug development company developing Aironite for cardiopulmonary indications such as pulmonary hypertension.  The company is headquartered in San Diego, California.


'/>"/>
SOURCE Aires Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Buenos Aires Welcomes CPhI South America 2010
2. T-System Provides Free Medical Documentation Templates and Bi-Lingual Triage Questionnaires for Haiti Relief Medical Personnel
3. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
5. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
6. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
7. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
9. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
10. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
11. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Brain Cancer patients in ... at West Cancer Center . Optune™, ... inhibit cancer cell replication causing death of cancer cells, ... decade to show a significant extension in overall survival ... Currently, West Cancer Center is the only medical center ...
(Date:2/11/2016)... ROCKLEDGE, Fla. , Feb. 11, 2016 ... have started out 2016 with sales exceeding company targets, ... and have received their trademark from the United States ... Bobby Clark , Chief Executive Officer of PLAD, ... state of Pennsylvania with two ...
(Date:2/11/2016)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... engagement of Lars E. Birgerson , M.D., ... Birgerson will provide strategic medical advisory and operational ... help ensure timely facilitation of new clinical trial ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Pixel Film ... users with customizable backdrops in the Christmas edition of the ProDrop series. Pick ... year. Captivate audiences and invoke the spirit of Christmas using ProDrop's wintry generators. ProDrop ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling ... in health and wellness best practices in the past couple of decades, and ... is American Heart Month, which acts as an exceptional opportunity to revise food ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the World Molecular Imaging Congress (WMIC), will be held in New York City, ... is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group ... associations of medical professionals throughout the country. The Guard was specifically designed to ... and procedures, employee training, regulatory updates, and compliance coaching. , In addition to ...
Breaking Medicine News(10 mins):